Cogent Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 164
- Market Cap
- $1B
- Website
- http://www.cogentbio.com
- Introduction
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario C...
(Peak) a Phase 3 Randomized Trial of CGT9486+Sunitinib Vs. Sunitinib in Subjects with Gastrointestinal Stromal Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 442
- Registration Number
- NCT05208047
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
🇮🇹Istituto Europeo di Oncologia, Milano, Italy
🇮🇹Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT05186753
- Locations
- 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
🇺🇸Allervie Clinical Research, Glenn Dale, Maryland, United States
🇺🇸Chesapeake Research Center, White Marsh, Maryland, United States
(Apex) Bezuclastinib in Patients with Advanced Systemic Mastocytosis
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04996875
- Locations
- 🇩🇪
UKSH Campus Lubeck, Lubeck, Germany
🇵🇱Public University Hospital No. 1 in Lublin, Lublin, Poland
🇺🇸University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama, United States
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
- Conditions
- Interventions
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03680560
- Locations
- 🇺🇸
Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Yale Smilow Cancer Hospital, New Haven, Connecticut, United States
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03266692
- Locations
- 🇺🇸
Baylor Scott & White, Dallas, Texas, United States
🇺🇸Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
🇺🇸Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT03189836
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Emory University, Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Loyola University, Maywood, Illinois, United States
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
- Conditions
- Interventions
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02840110
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Banner MD Anderson, Gilbert, Arizona, United States
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02776813
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Loyola University Chicago, Maywood, Illinois, United States
🇺🇸Indiana Bone and Marrow Transplantation, Indianapolis, Indiana, United States
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02401815
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸OSU Comprehensive Cancer Center, Columbus, Ohio, United States